FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 169 filers reported holding FATE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 9.78 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,816,481 | -90.2% | 2,271,925 | -78.0% | 0.00% | -100.0% |
| Q2 2023 | $49,094,216 | -41.9% | 10,313,911 | -30.5% | 0.00% | -40.0% |
| Q1 2023 | $84,531,479 | -29.4% | 14,830,084 | +24.9% | 0.01% | +25.0% |
| Q4 2022 | $119,777,562 | +22.0% | 11,870,918 | +170.9% | 0.00% | -33.3% |
| Q3 2022 | $98,215,000 | -24.8% | 4,382,634 | -16.8% | 0.01% | -25.0% |
| Q2 2022 | $130,594,000 | -3.0% | 5,270,135 | +51.8% | 0.01% | +14.3% |
| Q1 2022 | $134,626,000 | -15.4% | 3,472,432 | +27.7% | 0.01% | -12.5% |
| Q4 2021 | $159,077,000 | +12.7% | 2,718,793 | +14.2% | 0.01% | +14.3% |
| Q3 2021 | $141,154,000 | -20.8% | 2,381,539 | +15.9% | 0.01% | -22.2% |
| Q2 2021 | $178,314,000 | +9.1% | 2,054,546 | +3.6% | 0.01% | 0.0% |
| Q1 2021 | $163,515,000 | -14.7% | 1,983,196 | -5.9% | 0.01% | -25.0% |
| Q4 2020 | $191,623,000 | +65.2% | 2,107,373 | -27.4% | 0.01% | +50.0% |
| Q3 2020 | $115,997,000 | +9.0% | 2,902,108 | -6.4% | 0.01% | 0.0% |
| Q2 2020 | $106,417,000 | +94.3% | 3,101,641 | +25.8% | 0.01% | +60.0% |
| Q1 2020 | $54,760,000 | +17.4% | 2,465,539 | +3.4% | 0.01% | +66.7% |
| Q4 2019 | $46,657,000 | +10.8% | 2,384,132 | -12.0% | 0.00% | 0.0% |
| Q3 2019 | $42,098,000 | -14.6% | 2,710,736 | +11.6% | 0.00% | -25.0% |
| Q2 2019 | $49,289,000 | +8.1% | 2,428,026 | -6.5% | 0.00% | 0.0% |
| Q1 2019 | $45,615,000 | +74.8% | 2,596,179 | +27.7% | 0.00% | +100.0% |
| Q4 2018 | $26,091,000 | -18.1% | 2,033,588 | +4.0% | 0.00% | 0.0% |
| Q3 2018 | $31,843,000 | +40.8% | 1,954,840 | -2.0% | 0.00% | 0.0% |
| Q2 2018 | $22,615,000 | +194.3% | 1,993,912 | +153.3% | 0.00% | +100.0% |
| Q1 2018 | $7,685,000 | +135.2% | 787,163 | +47.1% | 0.00% | – |
| Q4 2017 | $3,267,000 | +81.9% | 534,969 | +17.9% | 0.00% | – |
| Q3 2017 | $1,796,000 | +25.0% | 453,661 | +2.3% | 0.00% | – |
| Q2 2017 | $1,437,000 | – | 443,462 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 569,889 | $51,820,000 | 67.63% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $307,258,000 | 39.62% |
| Darwin Global Management, Ltd. | 952,847 | $86,642,000 | 24.18% |
| Redmile Group, LLC | 12,629,737 | $1,148,422,000 | 13.91% |
| DAFNA Capital Management LLC | 334,360 | $30,403,000 | 9.05% |
| Casdin Capital, LLC | 3,050,000 | $277,337,000 | 8.22% |
| Grosvenor Holdings, L.L.C. | 1,459,517 | $132,714,000 | 7.23% |
| Copernicus Capital Management, LLC | 3,240 | $295,000 | 4.60% |
| Eversept Partners, LP | 399,499 | $36,326,444 | 4.26% |
| Ally Bridge Group (NY) LLC | 260,000 | $23,642,000 | 4.05% |